HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

William Stohl Selected Research

belimumab

11/2022Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
1/2022Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE.
1/2020Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents.
12/2019The safety of belimumab for the treatment of systemic lupus erythematosus.
1/2019Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
1/2018Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
1/2017Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
2/2014Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
12/2013Future prospects in biologic therapy for systemic lupus erythematosus.
5/2013Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


William Stohl Research Topics

Disease

36Systemic Lupus Erythematosus (Libman-Sacks Disease)
11/2022 - 08/2002
15Rheumatoid Arthritis
01/2021 - 01/2006
5Autoimmune Diseases (Autoimmune Disease)
01/2020 - 10/2002
5Inflammation (Inflammations)
01/2020 - 10/2006
5Rheumatic Diseases (Rheumatism)
12/2019 - 08/2002
3Infections
01/2022 - 02/2014
3Proteinuria
01/2020 - 05/2012
2Lupus Nephritis
11/2022 - 01/2009
2Tetanus
05/2014 - 08/2012
2Hypergammaglobulinemia (Hyperimmunoglobulinemia)
07/2012 - 07/2008
2Nephritis
02/2009 - 01/2009
2Arthritis (Polyarthritis)
10/2006 - 04/2003
1Spontaneous Abortion (Miscarriage)
10/2021
1Fatigue
01/2018
1Chronic Disease (Chronic Diseases)
01/2018
1Dry Eye Syndromes (Dry Eye Syndrome)
01/2018
1Dacryocystitis (Dacryoadenitis)
07/2014
1Human Influenza (Influenza)
08/2012
1Glomerulonephritis
04/2011
1Juvenile Arthritis (Juvenile Idiopathic Arthritis)
11/2009
1Interstitial Nephritis (Tubulointerstitial Nephritis)
07/2008
1Starvation
10/2006
1Stroke (Strokes)
10/2006
1Disease Progression
09/2002
1Opportunistic Infections (Opportunistic Infection)
08/2002
1Neoplasms (Cancer)
08/2002

Drug/Important Bio-Agent (IBA)

19B-Cell Activating FactorIBA
11/2022 - 08/2002
16belimumabIBA
11/2022 - 01/2008
12Immunoglobulin G (IgG)IBA
01/2022 - 08/2002
10AutoantibodiesIBA
01/2020 - 08/2002
7Biological ProductsIBA
12/2013 - 08/2002
6Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2009
5Proteins (Proteins, Gene)FDA Link
01/2020 - 08/2002
5AntibodiesIBA
12/2019 - 03/2006
4Monoclonal AntibodiesIBA
11/2022 - 10/2006
4Rituximab (Mabthera)FDA Link
01/2020 - 03/2006
4CytokinesIBA
01/2020 - 01/2010
3Methotrexate (Mexate)FDA LinkGeneric
01/2021 - 03/2012
3AntigensIBA
12/2019 - 02/2010
3EnzymesIBA
09/2015 - 04/2003
3ImmunosorbentsIBA
09/2015 - 04/2003
3DNA (Deoxyribonucleic Acid)IBA
07/2012 - 08/2008
3Messenger RNA (mRNA)IBA
11/2009 - 12/2003
3Estrogens (Estrogen)FDA Link
09/2009 - 08/2008
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2020 - 02/2010
2Immunoglobulin M (IgM)IBA
12/2019 - 05/2014
2LigandsIBA
12/2019 - 10/2002
2Tumor Necrosis Factor InhibitorsIBA
03/2017 - 02/2010
2B-Cell Activation Factor ReceptorIBA
09/2015 - 04/2013
2VaccinesIBA
08/2012 - 07/2012
2Pharmaceutical PreparationsIBA
08/2012 - 01/2012
2Antigen-Antibody Complex (Immune Complex)IBA
02/2010 - 10/2006
1JNJ-55920839IBA
04/2021
1GLPG0634IBA
01/2021
1Member 25 Tumor Necrosis Factor ReceptorsIBA
01/2020
1GlobulinsIBA
12/2019
1Serum GlobulinsIBA
12/2019
1C-Reactive ProteinIBA
12/2019
1Secretory Immunoglobulin A (SIgA)IBA
01/2018
1ProgranulinsIBA
03/2017
1AMG623 peptibodyIBA
08/2015
1B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA
05/2014
1Adrenal Cortex Hormones (Corticosteroids)IBA
02/2014
1Antirheumatic Agents (DMARD)IBA
02/2013
1ocrelizumabIBA
08/2012
1Complement System Proteins (Complement)IBA
07/2012
1Interleukin-4 (Interleukin 4)IBA
04/2011
1CalciumIBA
04/2011
1Interferon-betaIBA
02/2010
1Interferon Type IIBA
02/2010
1anti-dsDNA autoantibodyIBA
02/2009
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
02/2009
1Complement Factor B (Factor B)IBA
01/2008
1IsomerasesIBA
10/2006
1Protein Isoforms (Isoforms)IBA
01/2006
1N 30IBA
01/2006

Therapy/Procedure

9Therapeutics
11/2022 - 10/2006
1Biological Therapy
12/2013